| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ulrich Beuers | |
| Gustav Paumgartner | |||
| P2860 | cites work | The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity | Q24630723 |
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Stimulation of ATP secretion in the liver by therapeutic bile acids | Q28345188 | ||
| Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production | Q28379482 | ||
| Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers | Q32075349 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. | Q33834255 | ||
| Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis | Q33910573 | ||
| Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited | Q34146325 | ||
| Bile salt transporters: molecular characterization, function, and regulation | Q34186800 | ||
| Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. | Q34330984 | ||
| Death receptor-mediated apoptosis and the liver | Q34783540 | ||
| Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes | Q39606574 | ||
| Pharmacology of ursodeoxycholic acid, an enterohepatic drug. | Q40571618 | ||
| The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis | Q40737262 | ||
| Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | Q40784945 | ||
| Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. | Q40785589 | ||
| Characterization of the mouse bile salt export pump overexpressed in the baculovirus system | Q40807260 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study | Q41916901 | ||
| Effects of tauroursodeoxycholic acid on cytosolic Ca2+ signals in isolated rat hepatocytes | Q42509692 | ||
| A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease | Q42545724 | ||
| Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study | Q42551010 | ||
| Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. | Q42555482 | ||
| Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver | Q42797129 | ||
| Hepatoprotection with tauroursodeoxycholate and beta muricholate against taurolithocholate induced cholestasis: involvement of signal transduction pathways | Q43006246 | ||
| Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver | Q43601206 | ||
| Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver | Q43662715 | ||
| Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats | Q43697146 | ||
| A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis | Q43770466 | ||
| Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment | Q43878341 | ||
| Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes | Q43933924 | ||
| Ursodeoxycholic acid cytoprotection: dancing with death receptors and survival pathways | Q43933958 | ||
| Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha | Q43974813 | ||
| Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase-dependent manner | Q43976619 | ||
| Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities | Q44080027 | ||
| Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis | Q44139912 | ||
| Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles | Q44165186 | ||
| Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets | Q44355362 | ||
| Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo | Q47869512 | ||
| Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid. | Q51597193 | ||
| Bile acid structure and selective modulation of murine hepatic cytochrome P450-linked enzymes | Q57012049 | ||
| Bile acids with differing hydrophilic-hydrophobic properties do not influence cytokine production by human monocytes and murine Kupffer cells | Q57792073 | ||
| Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial | Q68019501 | ||
| Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver | Q68843723 | ||
| Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid | Q68925952 | ||
| Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
| Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? | Q69896715 | ||
| Molecular aspects of membrane stabilization by ursodeoxycholate [see comment] | Q70457384 | ||
| Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy | Q70670255 | ||
| Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes | Q71035961 | ||
| Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis | Q71173367 | ||
| Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis | Q71949350 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period | Q72503309 | ||
| Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group | Q73090826 | ||
| Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis | Q73107770 | ||
| Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study | Q73167014 | ||
| Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up | Q73317238 | ||
| Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes | Q73486365 | ||
| Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
| Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver | Q73760652 | ||
| Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes | Q74429593 | ||
| Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial | Q74644488 | ||
| Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications | Q77598543 | ||
| Modulation of protein kinase C by taurolithocholic acid in isolated rat hepatocytes | Q77906209 | ||
| Assessment of biliary bicarbonate secretion in humans by positron emission tomography | Q77921993 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 67-81, vi | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | Clinics in liver disease | Q26842322 |
| P1476 | title | Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease | |
| P478 | volume | 8 |
| Q26771816 | A review of the medical treatment of primary sclerosing cholangitis in the 21st century |
| Q40429203 | Activation of CREB by tauroursodeoxycholic acid protects cholangiocytes from apoptosis induced by mTOR inhibition |
| Q46595753 | Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis |
| Q55174800 | Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid |
| Q24234678 | Bile acids for primary sclerosing cholangitis |
| Q41095627 | Chemical chaperone, TUDCA unlike PBA, mitigates protein aggregation efficiently and resists ER and non-ER stress induced HepG2 cell death |
| Q38757248 | Child with Jaundice and Pruritus: How to Evaluate? |
| Q30513913 | Cholangiocyte cilia are abnormal in syndromic and non-syndromic biliary atresia |
| Q33709930 | Clinical application of transcriptional activators of bile salt transporters |
| Q42555450 | Combined endoscopic and ursodeoxycholic acid treatment of biliary cast syndrome in a non-transplant patient |
| Q36495172 | Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis |
| Q42605353 | Effect of quercetin on CYP3A activity in Chinese healthy participants |
| Q38751076 | Emerging pharmacologic therapies for primary sclerosing cholangitis |
| Q36429814 | Expression and function of renal and hepatic organic anion transporters in extrahepatic cholestasis |
| Q57760186 | Function of nuclear steroid receptors in apoptosis: role of ursodeoxycholic acid |
| Q37117971 | High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis |
| Q35172521 | Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study |
| Q34448448 | INTRACELLULAR SIGNALING BY BILE ACIDS. |
| Q39921876 | Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. |
| Q37418054 | Immune-mediated liver diseases: programmed cell death ligands and circulating apoptotic markers. |
| Q33579196 | Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis |
| Q92032230 | Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives |
| Q53622503 | Is ursodeoxycholic acid crucial for ischemia/reperfusion-induced ovarian injury in rat ovary? |
| Q34657625 | Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases |
| Q57150403 | Liver disease in infancy caused by oxysterol 7 α-hydroxylase deficiency: successful treatment with chenodeoxycholic acid |
| Q36606886 | Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. |
| Q34017604 | Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets |
| Q81724957 | Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q36579519 | Molecular mechanisms of cholestasis. |
| Q39094306 | Naturally Occurring Nrf2 Activators: Potential in Treatment of Liver Injury. |
| Q90456286 | Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function |
| Q84230884 | Primary biliary cirrhosis |
| Q46754743 | Protein kinase Cdelta mediates cyclic adenosine monophosphate-stimulated translocation of sodium taurocholate cotransporting polypeptide and multidrug resistant associated protein 2 in rat hepatocytes |
| Q36574505 | Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management. |
| Q33730935 | Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant |
| Q36879950 | Role of the Nrf2-ARE pathway in liver diseases |
| Q37250362 | Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease |
| Q40352370 | Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione |
| Q50438744 | Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate |
| Q46848216 | Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver |
| Q46884201 | The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid |
| Q28269374 | The bile salt export pump |
| Q34993108 | The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study |
| Q37101542 | The efficacy of pharmacological treatment in pediatric nonalcoholic Fatty liver disease |
| Q36914332 | The unfinished business of primary biliary cirrhosis |
| Q37611031 | UGT3A: novel UDP-glycosyltransferases of the UGT superfamily |
| Q55365658 | Ursodeoxycholate Restores Biliary Excretion of Methotrexate in Rats with Ethinyl Estradiol Induced-Cholestasis by Restoring Canalicular Mrp2 Expression. |
| Q92556677 | Ursodeoxycholic Acid Alters Bile Acid and Fatty Acid Profiles in a Mouse Model of Diet-Induced Obesity |
| Q38058981 | Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action |
| Q46440176 | Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice |
| Q37012207 | Ursodeoxycholic acid: Mechanism of action and novel clinical applications |
Search more.